Thirty-one percent of adult Americans are not simply overweight, they are clinically diagnosed as obese. This translates into 500 million people. Obesity has become one of the most serious threats to Americans health and well-being. Figures show that obesity rates in the United states have steadily risen over the last 25 years and have reached epidemic proportions.
It would take an army of accountants to forecast the medical and direct costs associated with obesity, but it is well documented that obesity is directly associated serious health issues such as heart attack, stroke, high blood pressure, and diabetes; making obesity one of the major factors that cause preventable death in U.S.
On the new product front, there is great news. Vivus Pharmaceuticals have recently announced a new weight loss pill, designated for considerable weight loss for obese patients. This groundbreaking medication is named Qsymia, a weight loss pill that was recently approved for prescription by the Food and drug administration.
The significance is that this medication was approved by the FDA this year; while the FDA has been reluctant to approve any weight loss medications in the last ten years. The pills performance has been noteworthy. Qsymia is a combination drug, consisting of two drugs, which are known to have varying degree of effectiveness with obese patients. Together is seems to be quite the combination.
This weight loss drug among other things, is approved under strenuous clinical study. Patients were monitored while on Qsymia for 12 consecutive months. In one study, patients lost an average of 6.7 per cent of body weight, while in the other, patients lost an average of 8.9 per cent. Patients on the highest dosages reported significant body weight loss as high as 22 pounds.
The drugs that make the weight loss pill so effective are Phentermine, an appetite suppressant and Topiramate, an anti-consultant that causes a patient to feel more satisfied after a meal. It is probable that Qsymia is effective because of its two-pronged attack on overeating.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; Equilibrium Weight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.
It would take an army of accountants to forecast the medical and direct costs associated with obesity, but it is well documented that obesity is directly associated serious health issues such as heart attack, stroke, high blood pressure, and diabetes; making obesity one of the major factors that cause preventable death in U.S.
On the new product front, there is great news. Vivus Pharmaceuticals have recently announced a new weight loss pill, designated for considerable weight loss for obese patients. This groundbreaking medication is named Qsymia, a weight loss pill that was recently approved for prescription by the Food and drug administration.
The significance is that this medication was approved by the FDA this year; while the FDA has been reluctant to approve any weight loss medications in the last ten years. The pills performance has been noteworthy. Qsymia is a combination drug, consisting of two drugs, which are known to have varying degree of effectiveness with obese patients. Together is seems to be quite the combination.
This weight loss drug among other things, is approved under strenuous clinical study. Patients were monitored while on Qsymia for 12 consecutive months. In one study, patients lost an average of 6.7 per cent of body weight, while in the other, patients lost an average of 8.9 per cent. Patients on the highest dosages reported significant body weight loss as high as 22 pounds.
The drugs that make the weight loss pill so effective are Phentermine, an appetite suppressant and Topiramate, an anti-consultant that causes a patient to feel more satisfied after a meal. It is probable that Qsymia is effective because of its two-pronged attack on overeating.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; Equilibrium Weight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.
About the Author:
If you want to know if Qsymia diet capsules are available close to you? You will need a doctors approval to get the Qsymia
No comments:
Post a Comment